# Bram Verstockt

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/9047590/publications.pdf

Version: 2024-02-01

| | | | |
|---|---|---|---|
| 179 papers | 5,703 citations | 147566 31 h-index | 88477 70 g-index |
| 183 all docs | 183 docs citations | 183 times ranked | 4889 citing authors |

| # | Article | IF | Citations |
|---|---|---|---|
| 1 | ECCO-ESGAR Guideline for Diagnostic Assessment in IBD Part 1: Initial diagnosis, monitoring of known IBD, detection of complications. Journal of Crohn's and Colitis, 2019, 13, 144-164K. | 0.6 | 958 |
| 2 | ECCO Guidelines on Therapeutics in Crohn's Disease: Medical Treatment. Journal of Crohn's and Colitis, 2020, 14, 4-22. | 0.6 | 741 |
| 3 | ECCO Guidelines on Therapeutics in Crohnâ€™s Disease: Surgical Treatment. Journal of Crohn's and Colitis, 2020, 14, 155-168. | 0.6 | 478 |
| 4 | ECCO Guidelines on Therapeutics in Ulcerative Colitis: Medical Treatment. Journal of Crohn's and Colitis, 2022, 16, 2-17. | 0.6 | 288 |
| 5 | ECCO-ESGAR Guideline for Diagnostic Assessment in IBD Part 2: IBD scores and general principles and technical aspects. Journal of Crohn's and Colitis, 2019, 13, 273-284. | 0.6 | 250 |
| 6 | ECCO Guidelines on the Prevention, Diagnosis, and Management of Infections in Inflammatory Bowel Disease. Journal of Crohn's and Colitis, 2021, 15, 879-913. | 0.6 | 177 |
| 7 | New treatment options for inflammatory bowel diseases. Journal of Gastroenterology, 2018, 53, 585-590. | 2.3 | 142 |
| 8 | Genetics of inflammatory bowel disease: beyond NOD2. The Lancet Gastroenterology and Hepatology, 2017, 2, 224-234. | 3.7 | 125 |
| 9 | Big data in IBD: big progress for clinical practice. Gut, 2020, 69, 1520-1532. | 6.1 | 121 |
| 10 | ECCO Guidelines on Therapeutics in Ulcerative Colitis: Surgical Treatment. Journal of Crohn's and Colitis, 2022, 16, 179-189. | 0.6 | 120 |
| 11 | Low TREM1 expression in whole blood predicts anti-TNF response in inflammatory bowel disease. EBioMedicine, 2019, 40, 733-742. | 2.7 | 119 |
| 12 | Evidence to Support Monitoring of Vedolizumab Trough Concentrations in Patients With Inflammatory Bowel Diseases. Clinical Gastroenterology and Hepatology, 2018, 16, 1937-1946.e8. | 2.4 | 113 |
| 13 | Long-term Clinical Effectiveness of Ustekinumab in Patients with Crohnâ€™s Disease Who Failed Biologic Therapies: A National Cohort Study. Journal of Crohn's and Colitis, 2019, 13, 1401-1409. | 0.6 | 92 |
| 14 | Ustekinumab Exposure-outcome Analysis in Crohnâ€™s Disease Only in Part Explains Limited Endoscopic Remission Rates. Journal of Crohn's and Colitis, 2019, 13, 864-872. | 0.6 | 83 |
| 15 | New biologics and small molecules in inflammatory bowel disease: an update. Therapeutic Advances in Gastroenterology, 2019, 12, 175628481985320. | 1.4 | 82 |
| 16 | Genomeâ€wide association studies in Crohn's disease: Past, present and future. Clinical and Translational Immunology, 2018, 7, e1001. | 1.7 | 80 |
| 17 | Postoperative Outcomes in Ustekinumab-Treated Patients Undergoing Abdominal Operations for Crohnâ€™s Disease. Journal of Crohn's and Colitis, 2018, 12, 402-407. | 0.6 | 66 |
| 18 | Breaking the therapeutic ceiling in drug development in ulcerative colitis. The Lancet Gastroenterology and Hepatology, 2021, 6, 589-595. | 3.7 | 65 |

| # | Article | IF | Citations |
|---|---|---|---|
| 19 | Influence of early adalimumab serum levels on immunogenicity and longâ€term outcome of antiâ€TNF naive Crohn's disease patients: the usefulness of rapid testing. Alimentary Pharmacology and Therapeutics, 2018, 48, 731-739. | 1.9 | 62 |
| 20 | Effectiveness and Safety of Vedolizumab in Anti-TNF-NaÃ¯ve Patients With Inflammatory Bowel Diseaseâ€"A Multicenter Retrospective European Study. Inflammatory Bowel Diseases, 2018, 24, 2442-2451. | 0.9 | 56 |
| 21 | Personalised medicine in Crohn's disease. The Lancet Gastroenterology and Hepatology, 2020, 5, 80-92. | 3.7 | 55 |
| 22 | Oncostatin M Is a Biomarker of Diagnosis, Worse Disease Prognosis, and Therapeutic Nonresponse in Inflammatory Bowel Disease. Inflammatory Bowel Diseases, 2021, 27, 1564-1575. | 0.9 | 53 |
| 23 | Mucosal IL13RA2 expression predicts nonresponse to antiâ€TNF therapy in Crohn's disease. Alimentary Pharmacology and Therapeutics, 2019, 49, 572-581. | 1.9 | 52 |
| 24 | A Matrix-based Model Predicts Primary Response to Infliximab in Crohnâ€™s Disease. Journal of Crohn's and Colitis, 2015, 9, 1120-1126. | 0.6 | 50 |
| 25 | Expression Levels of 4 Genes in Colon Tissue Might Be Used to Predict Which Patients Will Enter Endoscopic Remission After Vedolizumab Therapy for Inflammatory Bowel Diseases. Clinical Gastroenterology and Hepatology, 2020, 18, 1142-1151.e10. | 2.4 | 50 |
| 26 | Epithelial organoid cultures from patients with ulcerative colitis and Crohn's disease: a truly long-term model to study the molecular basis for inflammatory bowel disease?. Gut, 2017, 66, 2193-2195. | 6.1 | 43 |
| 27 | Sphingosine 1-phosphate modulation and immune cell trafficking in inflammatory bowel disease. Nature Reviews Gastroenterology and Hepatology, 2022, 19, 351-366. | 8.2 | 43 |
| 28 | TREM-1, the ideal predictive biomarker for endoscopic healing in anti-TNF-treated Crohnâ€™s disease patients?. Gut, 2019, 68, 1531-1533. | 6.1 | 42 |
| 29 | Gene and Mirna Regulatory Networks During Different Stages of Crohnâ€™s Disease. Journal of Crohn's and Colitis, 2019, 13, 916-930. | 0.6 | 41 |
| 30 | Oncostatin M as a new diagnostic, prognostic and therapeutic target in inflammatory bowel disease (IBD). Expert Opinion on Therapeutic Targets, 2019, 23, 943-954. | 1.5 | 40 |
| 31 | Results of the Seventh Scientific Workshop of ECCO: Precision Medicine in IBDâ€"Disease Outcome and Response to Therapy. Journal of Crohn's and Colitis, 2021, 15, 1431-1442. | 0.6 | 39 |
| 32 | ExÂVivo Mimicking of Inflammation in Organoids Derived From Patients With Ulcerative Colitis. Gastroenterology, 2020, 159, 1564-1567. | 0.6 | 36 |
| 33 | Ten-year survival after endoscopic stent placement as a bridge to surgery in obstructing colon cancer. Gastrointestinal Endoscopy, 2018, 87, 705-713.e2. | 0.5 | 34 |
| 34 | Estrogen receptor Î² controls proliferation of enteric glia and differentiation of neurons in the myenteric plexus after damage. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, 5798-5803. | 3.3 | 34 |
| 35 | Inflammatory Cutaneous Lesions in Inflammatory Bowel Disease Treated With Vedolizumab or Ustekinumab: An ECCO CONFER Multicentre Case Series. Journal of Crohn's and Colitis, 2020, 14, 1488-1493. | 0.6 | 34 |
| 36 | Intestinal Receptor of SARS-CoV-2 in Inflamed IBD Tissue Seems Downregulated by HNF4A in Ileum and Upregulated by Interferon Regulating Factors in Colon. Journal of Crohn's and Colitis, 2021, 15, 485-498. | 0.6 | 34 |

| # | Article | IF | Citations |
|---|---|---|---|
| 37 | Results of the Seventh Scientific Workshop of ECCO: Precision Medicine in IBDâ€"Prediction and Prevention of Inflammatory Bowel Disease. Journal of Crohn's and Colitis, 2021, 15, 1443-1454. | 0.6 | 33 |
| 38 | A safety assessment of biological therapies targeting the IL-23/IL-17 axis in inflammatory bowel diseases. Expert Opinion on Drug Safety, 2017, 16, 809-821. | 1.0 | 32 |
| 39 | Outcome of biological therapies in chronic antibioticâ€refractory pouchitis: A retrospective singleâ€centre experience. United European Gastroenterology Journal, 2019, 7, 1215-1225. | 1.6 | 32 |
| 40 | GlycA, a Nuclear Magnetic Resonance Spectroscopy Measure for Protein Glycosylation, is a Viable Biomarker for Disease Activity in IBD. Journal of Crohn's and Colitis, 2019, 13, 389-394. | 0.6 | 32 |
| 41 | How Do We Predict a Patientâ€™s Disease Course and Whether They Will Respond to Specific Treatments?. Gastroenterology, 2022, 162, 1383-1395. | 0.6 | 31 |
| 42 | Biological therapy targeting the IL-23/IL-17 axis in inflammatory bowel disease. Expert Opinion on Biological Therapy, 2017, 17, 31-47. | 1.4 | 29 |
| 43 | Results of the Seventh Scientific Workshop of ECCO: Precision Medicine in IBDâ€"What, Why, and How. Journal of Crohn's and Colitis, 2021, 15, 1410-1430. | 0.6 | 28 |
| 44 | Influence of Drug Exposure on Vedolizumab-Induced Endoscopic Remission in Anti-Tumour Necrosis Factor [TNF] NaÃ¯ve and Anti-TNF Exposed IBD Patients. Journal of Crohn's and Colitis, 2020, 14, 332-341. | 0.6 | 27 |
| 45 | Interstitial and Granulomatous Lung Disease in Inflammatory Bowel Disease Patients. Journal of Crohn's and Colitis, 2020, 14, 480-489. | 0.6 | 26 |
| 46 | Time to Revisit Disease Classification in Inflammatory Bowel Disease: Is the Current Classification of Inflammatory Bowel Disease Good Enough for Optimal Clinical Management?. Gastroenterology, 2022, 162, 1370-1382. | 0.6 | 26 |
| 47 | Immunogenicity is not the driving force of treatment failure in vedolizumabâ€treated inflammatory bowel disease patients. Journal of Gastroenterology and Hepatology (Australia), 2019, 34, 1175-1181. | 1.4 | 25 |
| 48 | Biological Therapy in Inflammatory Bowel Disease Patients Partly Restores Intestinal Innate Lymphoid Cell Subtype Equilibrium. Frontiers in Immunology, 2020, 11, 1847. | 2.2 | 25 |
| 49 | Understanding the Molecular Drivers of Disease Heterogeneity in Crohnâ€™s Disease Using Multi-omic Data Integration and Network Analysis. Inflammatory Bowel Diseases, 2021, 27, 870-886. | 0.9 | 24 |
| 50 | Role of Eosinophils in Intestinal Inflammation and Fibrosis in Inflammatory Bowel Disease: An Overlooked Villain?. Frontiers in Immunology, 2021, 12, 754413. | 2.2 | 24 |
| 51 | Monitoring vedolizumab and ustekinumab drug levels in patients with inflammatory bowel disease: hype or hope?. Current Opinion in Pharmacology, 2020, 55, 17-30. | 1.7 | 23 |
| 52 | Genetic Influences on the Development of Fibrosis in Crohnâ€™s Disease. Frontiers in Medicine, 2016, 3, 24. | 1.2 | 21 |
| 53 | Computational Biology and Machine Learning Approaches to Understand Mechanistic Microbiome-Host Interactions. Frontiers in Microbiology, 2021, 12, 618856. | 1.5 | 19 |
| 54 | Effects of Epithelial IL-13RÎ±2 Expression in Inflammatory Bowel Disease. Frontiers in Immunology, 2018, 9, 2983. | 2.2 | 17 |

| # | Article | IF | Citations |
|---|---|---|---|
| 55 | ECCO Topical Review: Refractory Inflammatory Bowel Disease. Journal of Crohn's and Colitis, 2021, 15, 1605-1620. | 0.6 | 16 |
| 56 | Meta-analysis of gene expression disease signatures in colonic biopsy tissue from patients with ulcerative colitis. Scientific Reports, 2021, 11, 18243. | 1.6 | 14 |
| 57 | Monocyte TREM-1 Levels Associate With Anti-TNF Responsiveness in IBD Through Autophagy and FcÎ³-Receptor Signaling Pathways. Frontiers in Immunology, 2021, 12, 627535. | 2.2 | 13 |
| 58 | Neutrophilic HGF-MET Signalling Exacerbates Intestinal Inflammation. Journal of Crohn's and Colitis, 2020, 14, 1748-1758. | 0.6 | 12 |
| 59 | Tailoring Multi-omics to Inflammatory Bowel Diseases: All for One and One for All. Journal of Crohn's and Colitis, 2022, 16, 1306-1320. | 0.6 | 11 |
| 60 | Impact of firstâ€line infliximab on the pharmacokinetics of secondâ€line vedolizumab in inflammatory bowel diseases. United European Gastroenterology Journal, 2019, 7, 750-758. | 1.6 | 10 |
| 61 | DOP70 An integrated multi-omics biomarker predicting endoscopic response in ustekinumab treated patients with Crohn's disease. Journal of Crohn's and Colitis, 2019, 13, S072-S073. | 0.6 | 9 |
| 62 | Clostridium difficile infection in inflammatory bowel disease: epidemiology over two decades. European Journal of Gastroenterology and Hepatology, 2019, 31, 668-673. | 0.8 | 9 |
| 63 | Thiopurine monotherapy has a limited place in treatment of patients with mild-to-moderate Crohnâ€™s disease. Gut, 2021, 70, 1416-1418. | 6.1 | 9 |
| 64 | Population pharmacokineticâ€pharmacodynamic modelâ€based exploration of alternative ustekinumab dosage regimens for patients with Crohn's disease. British Journal of Clinical Pharmacology, 2022, 88, 323-335. | 1.1 | 9 |
| 65 | A systems genomics approach to uncover patient-specific pathogenic pathways and proteins in ulcerative colitis. Nature Communications, 2022, 13, 2299. | 5.8 | 9 |
| 66 | Real-world Endoscopic and Histological Outcomes Are Correlated with Ustekinumab Exposure in Patients with Ulcerative Colitis. Journal of Crohn's and Colitis, 2022, 16, 1562-1570. | 0.6 | 9 |
| 67 | Invasive nocardiosis, disseminated varicella zoster reactivation, and pneumocystis jiroveci pneumonia associated with tofacitinib and concomitant systemic corticosteroid use in ulcerative colitis. Journal of Gastroenterology and Hepatology (Australia), 2020, 35, 2294-2297. | 1.4 | 8 |
| 68 | Short- and Long-term Outcomes Following Side-to-side Strictureplasty and its Modification Over the Ileocaecal Valve for Extensive Crohnâ€™s Ileitis. Journal of Crohn's and Colitis, 2020, 14, 1378-1384. | 0.6 | 8 |
| 69 | Point-of-care intestinal ultrasonography in inflammatory bowel disease. Nature Reviews Gastroenterology and Hepatology, 2021, 18, 209-210. | 8.2 | 8 |
| 70 | The effect of aging on infliximab exposure and response in patients with inflammatory bowel diseases. British Journal of Clinical Pharmacology, 2021, 87, 3776-3789. | 1.1 | 8 |
| 71 | Etrolizumab for ulcerative colitis: beyond what meets the eye. The Lancet Gastroenterology and Hepatology, 2022, 7, 2-4. | 3.7 | 8 |
| 72 | Microbiota, not host origin drives ex vivo intestinal epithelial responses. Gut Microbes, 2022, 14, . | 4.3 | 8 |

| # | Article | IF | Citations |
|---|---|---|---|
| 73 | When IBD is not IBD. Scandinavian Journal of Gastroenterology, 2018, 53, 1085-1088. | 0.6 | 7 |
| 74 | Tissue Exposure does not Explain Non-Response in Ulcerative Colitis Patients with Adequate Serum Vedolizumab Concentrations. Journal of Crohn's and Colitis, 2021, 15, 988-993. | 0.6 | 7 |
| 75 | Results of the Seventh Scientific Workshop of ECCO: Precision Medicine in IBD â€“ Challenges and Future Directions. Journal of Crohn's and Colitis, 2021, 15, 1407-1409. | 0.6 | 7 |
| 76 | Diagnosis and Outcome of Extranodal Primary Intestinal Lymphoma in Inflammatory Bowel Disease: An ECCO CONFER Case Series. Journal of Crohn's and Colitis, 2022, 16, 500-505. | 0.6 | 7 |
| 77 | Integrated analysis of microbe-host interactions in Crohnâ€™s disease reveals potential mechanisms of microbial proteins on host gene expression. IScience, 2022, 25, 103963. | 1.9 | 7 |
| 78 | Biomarker discovery for personalized therapy selection in inflammatory bowel diseases: Challenges and promises. Current Research in Pharmacology and Drug Discovery, 2022, 3, 100089. | 1.7 | 6 |
| 79 | Health Literacy and Quality of Life in Young Adults From The Belgian Crohn's Disease Registry Compared to Type 1 Diabetes Mellitus. Frontiers in Pediatrics, 2021, 9, 624416. | 0.9 | 5 |
| 80 | Translating Results from VARSITY to Real World: Adalimumab vs Vedolizumab as First-line Biological in Moderate to Severe IBD. Inflammatory Bowel Diseases, 2022, 28, 1135-1142. | 0.9 | 5 |
| 81 | Longitudinal monitoring of <scp>STAT3</scp> phosphorylation and histologic outcome of tofacitinib therapy in patients with ulcerative colitis. Alimentary Pharmacology and Therapeutics, 2022, 56, 282-291. | 1.9 | 5 |
| 82 | Hereditary Colorectal Cancer Syndromes and Inflammatory Bowel Diseases: an ECCO CONFER Multicentre Case Series. Journal of Crohn's and Colitis, 2022, 16, 1845-1852. | 0.6 | 5 |
| 83 | P342 A population pharmacokinetic model to support therapeutic drug monitoring during vedolizumab therapy. Journal of Crohn's and Colitis, 2019, 13, S273-S274. | 0.6 | 4 |
| 84 | Molecular Changes in the Non-Inflamed Terminal Ileum of Patients with Ulcerative Colitis. Cells, 2020, 9, 1793. | 1.8 | 4 |
| 85 | Editorial: a clinical decision tool to identify patients who might benefit most from intensified dosing in the biological eraâ€”getting nearer?. Alimentary Pharmacology and Therapeutics, 2020, 51, 737-738. | 1.9 | 4 |
| 86 | P062 Effects of exposure to steroids on the PredictSURE whole blood prognostic assay in Inflammatory Bowel Disease. Journal of Crohn's and Colitis, 2021, 15, S168-S168. | 0.6 | 4 |
| 87 | Orofacial Granulomatosis Associated with Crohnâ€™s Disease: a Multicentre Case Series. Journal of Crohn's and Colitis, 2022, 16, 430-435. | 0.6 | 4 |
| 88 | Impact on aerosol generation during upper endoscopy of mouthpiece designed to reduce COVID-19 droplet spread: single-center randomized controlled trial. Endoscopy, 2021, 54, . | 1.0 | 4 |
| 89 | Inflammatory Bowel Disease (IBD)â€”A Textbook Case for Multi-Centric Banking of Human Biological Materials. Frontiers in Medicine, 2019, 6, 230. | 1.2 | 3 |
| 90 | Immune therapies in ulcerative colitis: are we beyond anti-TNF yet?. The Lancet Gastroenterology and Hepatology, 2020, 5, 794-796. | 3.7 | 3 |

| # | Article | IF | Citations |
|---|---|---|---|
| 91 | P061 The molecular landscape of perianal fistula in Crohnâ€™s disease: opportunities for new therapeutic approaches. Journal of Crohn's and Colitis, 2020, 14, S165-S165. | 0.6 | 3 |
| 92 | Point-of-Care Intestinal Ultrasound Examination: Prime Time for the Management of Ulcerative Colitis?. Gastroenterology, 2021, 160, 964-965. | 0.6 | 3 |
| 93 | P399 Endoscopic and histologic outcome in tofacitinib treated refractory moderate-to-severe ulcerative colitis: A prospective real-life cohort. Journal of Crohn's and Colitis, 2020, 14, S369-S370. | 0.6 | 3 |
| 94 | P442 Real-world endoscopic and histologic outcomes are linked to ustekinumab exposure in Ulcerative Colitis. Journal of Crohn's and Colitis, 2022, 16, i424-i424. | 0.6 | 3 |
| 95 | DOP81 Baseline whole-blood gene expression of TREM1 does not predict clinical or endoscopic outcomes following adalimumab treatment in patients with Ulcerative Colitis or Crohnâ€™s Disease in the SERENE studies. Journal of Crohn's and Colitis, 2022, 16, i124-i125. | 0.6 | 3 |
| 96 | Higher Drug Exposure During the First 24 Weeks of Ustekinumab Treatment Is Associated With Endoscopic Remission in Crohnâ€™s Disease. Clinical Gastroenterology and Hepatology, 2023, 21, 838-840.e2. | 2.4 | 3 |
| 97 | Mapping the epithelialâ€“immune cell interactome upon infection in the gut and the upper airways. Npj Systems Biology and Applications, 2022, 8, 15. | 1.4 | 3 |
| 98 | Increased Baseline TNF-Driven Pathways Observed in Patients with Crohn's Disease not Responding to Infliximab. Gastroenterology, 2017, 152, S767. | 0.6 | 2 |
| 99 | DOP018 Baseline ILC1 distribution in blood predicts response to ustekinumab in patients with refractory Crohnâ€™s disease. Journal of Crohn's and Colitis, 2018, 12, S041-S042. | 0.6 | 2 |
| 100 | DOP26 Biological therapy increases NCR+ ILC3 levels in IBD patients. Journal of Crohn's and Colitis, 2019, 13, S040-S040. | 0.6 | 2 |
| 101 | OP11 Organoids derived from inflamed intestinal biopsies of patients with ulcerative colitis lose their inflammatory phenotype during ex vivo culture. Journal of Crohn's and Colitis, 2019, 13, S007-S007. | 0.6 | 2 |
| 102 | P601 Development and validation of dried blood spot sampling as a tool to identify the best time point to measure predictive ustekinumab serum concentrations in patients with Crohnâ€™s disease. Journal of Crohn's and Colitis, 2020, 14, S502-S502. | 0.6 | 2 |
| 103 | Long-term clinical outcome after thiopurine discontinuation in elderly IBD patients. Scandinavian Journal of Gastroenterology, 2021, 56, 1323-1327. | 0.6 | 2 |
| 104 | P401 Tofacitinib tissue exposure correlates with endoscopic outcome. Journal of Crohn's and Colitis, 2022, 16, i394-i395. | 0.6 | 2 |
| 105 | N18 Introduction of inflammatory bowel disease specialized dietitian and nutritional status in a multidisciplinary IBD team. Journal of Crohn's and Colitis, 2022, 16, i624-i625. | 0.6 | 2 |
| 106 | DOP79 Biomarkers for IBD using OLINK Proteomics inflammation panel: Preliminary results from the COLLIBRI consortium. Journal of Crohn's and Colitis, 2022, 16, i123-i124. | 0.6 | 2 |
| 107 | Letter: immunogenicity is not the root cause for loss of response to antiâ€•<scp>TNF</scp> agents in patients with <scp>IBD</scp> in <scp>TDM</scp> era. Alimentary Pharmacology and Therapeutics, 2022, 55, 885-886. | 1.9 | 2 |
| 108 | Ulcerative colitis, a transmural disease requiring an accurate IUS assessment in the current treatâ€toâ€target era. United European Gastroenterology Journal, 2022, 10, 247-248. | 1.6 | 2 |

| # | Article | IF | Citations |
|---|---|---|---|
| 109 | P035 Serum markers predict outcome to ustekinumab in patients with refractory Crohnâ€™s disease and provide insides in the mechanism of action. Journal of Crohn's and Colitis, 2018, 12, S110-S110. | 0.6 | 1 |
| 110 | P704 Ustekinumab induces limited mucosal healing after 6 months in a real-life, prospective cohort of patients with refractory Crohnâ€™s disease. Journal of Crohn's and Colitis, 2018, 12, S467-S467. | 0.6 | 1 |
| 111 | Mo1880 - Ustekinumab Induces Limited Mucosal Healing after 6 Months in a Real-Life, Prospective Cohort of Patients with Refractory Crohn's Disease. Gastroenterology, 2018, 154, S-836. | 0.6 | 1 |
| 112 | DOP33 Long-term clinical efficacy of ustekinumab in refractory Crohnâ€™s disease : a multi-centre Belgian cohort study. Journal of Crohn's and Colitis, 2019, 13, S044-S045. | 0.6 | 1 |
| 113 | DOP37 Vedolizumab-induced endoscopic remission in anti-TNF exposed and anti-TNF naÃ¯ve IBD patients: a large single-centre experience. Journal of Crohn's and Colitis, 2019, 13, S047-S048. | 0.6 | 1 |
| 114 | DOP38 A vedolizumab specific four-gene colonic signature accurately predicting future endoscopic remission in patients with inflammatory bowel disease. Journal of Crohn's and Colitis, 2019, 13, S048-S048. | 0.6 | 1 |
| 115 | P542 Efficacy and safety of biological therapies in chronic antibiotic-refractory pouchitis: a retrospective single-centre experience. Journal of Crohn's and Colitis, 2019, 13, S385-S385. | 0.6 | 1 |
| 116 | P836 The predictive role of gut microbiota in treatment response to vedolizumab and ustekinumab in inflammatory bowel disease. Journal of Crohn's and Colitis, 2019, 13, S542-S542. | 0.6 | 1 |
| 117 | P464 Vedolizumab concentrations in colonic mucosal tissue of ulcerative colitis patients inversely correlate with the severity of inflammation. Journal of Crohn's and Colitis, 2020, 14, S411-S412. | 0.6 | 1 |
| 118 | P641 An increased baseline mucosal TNF burden linked to adalimumab non-response: opportunities for therapeutic drug monitoring. Journal of Crohn's and Colitis, 2020, 14, S531-S532. | 0.6 | 1 |
| 119 | Tofacitinib and Subacute Pneumonitis: Donâ€™t Hold Your Breath. Journal of Crohn's and Colitis, 2021, 15, 692-693. | 0.6 | 1 |
| 120 | OP09 Patient reported outcomes reflect histologic disease activity in patients with Ulcerative Colitis: Interim analysis of the APOLLO study. Journal of Crohn's and Colitis, 2021, 15, S008-S009. | 0.6 | 1 |
| 121 | Selecting the Ideal Candidate for Anti-TNF Discontinuation in Crohnâ€™s Disease, Dream or Reality?. Gastroenterology, 2021, 161, 353-355. | 0.6 | 1 |
| 122 | P004 Microbiota, not host origin drives ex vivo epithelial response in ulcerative colitis patients and non-IBD controls. Journal of Crohn's and Colitis, 2022, 16, i136-i136. | 0.6 | 1 |
| 123 | DOP17 Evaluating segmental healing with the modified Mayo endoscopic score (MMES) has a clear additional value in predicting long-term outcome in patients with Ulcerative Colitis: Results from a prospective cohort study. Journal of Crohn's and Colitis, 2022, 16, i066-i067. | 0.6 | 1 |
| 124 | OP30 Upadacitinib modulates inflammatory pathways in gut tissue in patients with Ulcerative Colitis: Transcriptomic profiling from the Phase 2b study, U-ACHIEVE. Journal of Crohn's and Colitis, 2022, 16, i033-i034. | 0.6 | 1 |
| 125 | The Road to Prognostication? A Five-Protein Panel Predicting Disease Course in Inflammatory Bowel Disease. Gastroenterology, 2022, 162, 2123-2125. | 0.6 | 1 |
| 126 | Molecular Profiling of Early Crohn's Disease Using the Post-Operative Recurrence Model. Gastroenterology, 2017, 152, S79-S80. | 0.6 | 0 |

| # | Article | IF | Citations |
|---|---|---|---|
| 127 | P035 TNF-driven pathways are increased at baseline in Crohn's disease patients not responding to infliximab. Journal of Crohn's and Colitis, 2017, 11, S96-S97. | 0.6 | 0 |
| 128 | P527 Low adalimumab serum levels at Week 4 provoke immunogenicity and influence therapy outcome in anti-TNF naÃ¯ve Crohnâ€™s disease patients. Journal of Crohn's and Colitis, 2018, 12, S373-S373. | 0.6 | 0 |
| 129 | P042 Decreased leukocyte trafficking may contribute to vedolizumab refractory disease after anti-TNF exposure in patients with ulcerative colitis. Journal of Crohn's and Colitis, 2018, 12, S113-S113. | 0.6 | 0 |
| 130 | DOP003 Ustekinumab induces clinical and biological remission in biologic refractory Crohnâ€™s disease patients: A real-world belgian cohort study. Journal of Crohn's and Colitis, 2018, 12, S031-S032. | 0.6 | 0 |
| 131 | P032 Hepatocyte growth factor and MET in ulcerative colitis, novel drug targets impairing neutrophil recruitment?. Journal of Crohn's and Colitis, 2019, 13, S102-S102. | 0.6 | 0 |
| 132 | OP10 Systems genomics of ulcerative colitis: combining GWAS and signalling networks for patient stratification and individualised drug targeting in ulcerative colitis. Journal of Crohn's and Colitis, 2019, 13, S006-S007. | 0.6 | 0 |
| 133 | P821 Distinct and common gene expression profiles between inflamed ileum and colon of newly diagnosed CD patients. Journal of Crohn's and Colitis, 2019, 13, S533-S533. | 0.6 | 0 |
| 134 | P011 Signalling and transcriptional network propagation uncovers novel ulcerative colitis pathogenetic pathways from single-nucleotide polymorphisms. Journal of Crohn's and Colitis, 2019, 13, S091-S092. | 0.6 | 0 |
| 135 | P478 Immunogenicity is not the driving force of treatment failure in vedolizumab-treated inflammatory bowel disease patients. Journal of Crohn's and Colitis, 2019, 13, S351-S351. | 0.6 | 0 |
| 136 | P827 Up-regulation of IL17-related pathways in affected colon from ulcerative colitis compared with Crohnâ€™s disease. Journal of Crohn's and Colitis, 2019, 13, S537-S538. | 0.6 | 0 |
| 137 | Editorial: biomarker predictors of nonâ€response to <scp>TNF</scp>Î± antagonists â€” the quest continues. Authorsâ€™ reply. Alimentary Pharmacology and Therapeutics, 2019, 49, 1091-1092. | 1.9 | 0 |
| 138 | P385 TREM1, the first anti-TNF specific biomarker guiding therapeutic decision. Journal of Crohn's and Colitis, 2019, 13, S300-S300. | 0.6 | 0 |
| 139 | Invited Editorial: Targeting Alpha 4 Beta 7, More Trafficking Inhibition Than We Thought?. Journal of Crohn's and Colitis, 2020, 14, 1183-1184. | 0.6 | 0 |
| 140 | P145 Orofacial granulomatosis in Crohnâ€™s disease: an ECCO CONFER multi-centre case series. Journal of Crohn's and Colitis, 2020, 14, S209-S210. | 0.6 | 0 |
| 141 | P391 Side-to-side strictureplasty and its modification over the ileocecal valve for extensive Crohnâ€™s ileitis: single-centre long-term outcome. Journal of Crohn's and Colitis, 2020, 14, S365-S366. | 0.6 | 0 |
| 142 | P542 The effect of age on infliximab pharmacokinetics in patients with inflammatory bowel disease. Journal of Crohn's and Colitis, 2020, 14, S462-S463. | 0.6 | 0 |
| 143 | Tofacitinib, twoâ€faced Janus in ulcerative colitis and Crohnâ€™s disease?. United European Gastroenterology Journal, 2020, 8, 753-754. | 1.6 | 0 |
| 144 | DOP22 Integrative -omic analysis reveals microbiota mediated molecular mechanisms influencing host mucosal gene expression in Crohnâ€™s Disease. Journal of Crohn's and Colitis, 2021, 15, S061-S062. | 0.6 | 0 |

| # | Article | IF | Citations |
|---|---|---|---|
| 145 | P063 The immunological landscape of intestinal fibrosis in Crohnâ€™s Disease. Journal of Crohn's and Colitis, 2021, 15, S168-S169. | 0.6 | 0 |
| 146 | OP14 Extracellular RNAs as liquid biopsy non-invasive biomarker in IBD. Journal of Crohn's and Colitis, 2021, 15, S014-S015. | 0.6 | 0 |
| 147 | Su433 MODEL-BASED IDENTIFICATION OF AN OPTIMIZED USTEKINUMAB DOSAGE REGIMEN FOR PATIENTS WITH CROHN'S DISEASE. Gastroenterology, 2021, 160, S-687. | 0.6 | 0 |
| 148 | P095 Initial disease course in a Belgian, prospective inception cohort of patients with inflammatory bowel disease: the PANTHER cohort. Journal of Crohn's and Colitis, 2021, 15, S192-S193. | 0.6 | 0 |
| 149 | P361 No increased postoperative risk of venous thromboembolism in patients with Ulcerative Colitis undergoing colectomy after tofacitinib exposure. Journal of Crohn's and Colitis, 2021, 15, S380-S380. | 0.6 | 0 |
| 150 | P309 Are results from VARSITY applicable to real world? Adalimumab versus vedolizumab as first line biological in moderate-to-severe IBD. Journal of Crohn's and Colitis, 2021, 15, S336-S337. | 0.6 | 0 |
| 151 | DOP08 Serum proteomics predict endoscopic remission in patients with Crohnâ€™s Disease. Journal of Crohn's and Colitis, 2021, 15, S046-S047. | 0.6 | 0 |
| 152 | P465 One year endoscopic and histologic outcomes to tofacitinib therapy in refractory ulcerative colitis. Journal of Crohn's and Colitis, 2021, 15, S456-S457. | 0.6 | 0 |
| 153 | Su438 THE EFFECT OF AGING ON INFLIXIMAB EXPOSURE AND RESPONSE IN PATIENTS WITH INFLAMMATORY BOWEL DISEASES. Gastroenterology, 2021, 160, S-689. | 0.6 | 0 |
| 154 | Su462 ONE YEAR ENDOSCOPIC AND HISTOLOGIC OUTCOMES TO TOFACITINIB THERAPY IN REFRACTORY ULCERATIVE COLITIS. Gastroenterology, 2021, 160, S-702. | 0.6 | 0 |
| 155 | P307 Modelling of the relationship between ustekinumab exposure, faecal calprotectin and endoscopic outcomes in patients with Crohnâ€™s disease. Journal of Crohn's and Colitis, 2021, 15, S335-S336. | 0.6 | 0 |
| 156 | P027 Epithelial cells of patients with ulcerative colitis do not show an increased sensitivity after microbiota stimulation compared to non-IBD controls. Journal of Crohn's and Colitis, 2021, 15, S142-S143. | 0.6 | 0 |
| 157 | DOP07 Ulcerative Colitis associated single nucleotide polymorphisms found in transcription factor binding sites effect key pathogenesis pathways and facilitate patient stratification. Journal of Crohn's and Colitis, 2021, 15, S045-S046. | 0.6 | 0 |
| 158 | P311 Intensive dried blood spot sampling shows a higher drug exposure throughout the first 24 weeks of therapy in ustekinumab-treated Crohnâ€™s disease patients achieving endoscopic remission. Journal of Crohn's and Colitis, 2021, 15, S338-S339. | 0.6 | 0 |
| 159 | DOP37 Large differences in IBD care and education across Europe, first results of the pan-European VIPER survey. Journal of Crohn's and Colitis, 2021, 15, S075-S076. | 0.6 | 0 |
| 160 | Integrated Analysis of Microbe-Host Interactions in Crohn's Disease Reveals Potential Mechanistic Effects of Microbial Proteins on Host Gene Expression. SSRN Electronic Journal, 0, , . | 0.4 | 0 |
| 161 | S808â€ƒMechanisms of Non-Response to Adalimumab on Inflammatory Bowel Disease: Peripheral Proteomic and Transcriptomic Profiling from the SERENE-CD and SERENE-UC Studies. American Journal of Gastroenterology, 2021, 116, S375-S376. | 0.2 | 0 |
| 162 | Genetic Influences on the Development of Fibrosis in Inflammatory Bowel Disease. , 2018, , 13-38. | | 0 |

| # | Article | IF | Citations |
|---|---|---|---|
| 163 | 817â€ƒIdentification of Biomarkers and Mechanistic Insight for Upadacitinib in Crohnâ€™s Disease: Serum Inflammatory Mediator Analysis From the Phase 2b CELEST Study. American Journal of Gastroenterology, 2019, 114, S471-S471. | 0.2 | 0 |
| 164 | HMO-1â€...Variation in IBD care and education across Europe results from a pan-European survey. , 2021, , . | | 0 |
| 165 | P441 Adalimumab versus ustekinumab as first-line biological in a real-life cohort of moderate-to-severe Crohnâ€™s disease. Journal of Crohn's and Colitis, 2022, 16, i423-i424. | 0.6 | 0 |
| 166 | P041 Characterization of cytokine and drug concentrations in serum, mucosa and faeces during induction treatment of moderate-to-severe ulcerative colitis with anti-TNF monoclonal antibodies. Journal of Crohn's and Colitis, 2022, 16, i157-i158. | 0.6 | 0 |
| 167 | DOP89 Infliximab and ustekinumab clearance during induction predicts post-induction endoscopic outcomes in patients with Crohnâ€™s Disease. Journal of Crohn's and Colitis, 2022, 16, i131-i132. | 0.6 | 0 |
| 168 | P591 Biological therapies and small molecules show to be efficacious in patients with moderate-to-severe ulcerative proctitis. Journal of Crohn's and Colitis, 2022, 16, i528-i529. | 0.6 | 0 |
| 169 | P082 The profibrogenic role of neutrophil extracellular traps in stenotic Crohnâ€™s disease: a new antifibrotic target?. Journal of Crohn's and Colitis, 2022, 16, i182-i183. | 0.6 | 0 |
| 170 | P119 Hereditary Colorectal Cancer Syndromes and Inflammatory Bowel Diseases: an ECCO CONFER Multicenter Case Series. Journal of Crohn's and Colitis, 2022, 16, i210-i210. | 0.6 | 0 |
| 171 | P073 Eosinophil depletion partially protects from colonic inflammation, but increases colonic collagen deposition in a DSS colitis model. Journal of Crohn's and Colitis, 2022, 16, i177-i178. | 0.6 | 0 |
| 172 | P475 Profiling the use of Complementary Alternative Medicines among IBD patients. Journal of Crohn's and Colitis, 2022, 16, i445-i446. | 0.6 | 0 |
| 173 | P030 Distinct molecular profiles between idiopathic cryptoglandular and Crohn-related perianal fistulas. Journal of Crohn's and Colitis, 2022, 16, i151-i151. | 0.6 | 0 |
| 174 | DOP08 Transcriptional signatures of blood derived immune cells associated with disease location-based heterogeneity in IBD. Journal of Crohn's and Colitis, 2022, 16, i058-i058. | 0.6 | 0 |
| 175 | P496 Efficacy and safety of ustekinumab for chronic antibiotic refractory pouchitis: A Belgian open-label multicentre pilot study. Journal of Crohn's and Colitis, 2022, 16, i460-i461. | 0.6 | 0 |
| 176 | P647 Idiopathic Thrombocytopenic Purpura associated with Inflammatory Bowel Disease: a multi-centre ECCO CONFER case series. Journal of Crohn's and Colitis, 2022, 16, i561-i561. | 0.6 | 0 |
| 177 | P447 Positioning of ustekinumab affects its effectiveness, drug persistence and serum exposure in Crohnâ€™s disease. Journal of Crohn's and Colitis, 2022, 16, i427-i428. | 0.6 | 0 |
| 178 | P257 The clinical decision support tool has low performance in predicting outcome to ustekinumab in Crohnâ€™s disease. Journal of Crohn's and Colitis, 2022, 16, i298-i299. | 0.6 | 0 |
| 179 | An unusual cause of severe, persistent diarrhoea. Acta Gastro-Enterologica Belgica, 2017, 80, 416-418. | 0.4 | 0 |